GE Healthcare is launching Biacore 4000, a solution for large-scale, label-free molecular interaction analysis in drug discovery, from early screening to characterisation.
Biacore 4000 delivers high-quality binding, kinetic, affinity, concentration and specificity data in screening assays and detailed characterisation studies.
The system is designed for large-scale parallel-interaction analyses, with the capability to analyse up to 4,800 interactions in 24hrs.
Biacore 4000 is supported by dedicated software packages for the key drug-discovery application areas of small molecule discovery, and antibody screening and characterisation.
In combination with the LMW Extension Package software, the Biacore 4000 delivers the sensitivity, throughput and high-quality data required for fragment screening, lead selection and optimisation.
The system rapidly discriminates between well-behaved and promiscuous/atypical binders and presents streamlined, customised data evaluation.
Additional kinetic fitting models provide increased flexibility for compound-interaction analysis.
Data generated can be easily exported for customised analysis and workflow integration.
The Antibody Extension Package is said to enable Biacore 4000 users to get the best out of their system for antibody-analysis applications, saving time and reagents in biotherapeutic development.
Dedicated software tools for high-throughput kinetic studies and epitope mapping enable rapid identification of promising candidates.
Decision-critical kinetic information is generated twice as fast as with traditional multi-cycle kinetic assays, using the two-over-two kinetic approach.
